TP
MYGN icon

Traxis Partners’s Myriad Genetics MYGN Stock Holding History

Traxis Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-80,000
Closed -$2.15M – 25
2013
Q2 		$2.15M Buy
+80,000
New +$2.32M 1.66% 30

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Traxis Partners's MYGN Position: Q3 2013 in Review

Traxis Partners sold out of Myriad Genetics (MYGN) in Q3 2013, closing a stake of 80,000 shares — an estimated $2.15M sold.

Traxis Partners first reported a position in MYGN in Q2 2013 and held it in 1 quarter. The position peaked at $2.15M in Q2 2013. 267 funds tracked by Wall St. Rank hold MYGN as of Q3 2013.

  • Traxis Partners reported no remaining Myriad Genetics position as of Q3 2013 after selling out during the quarter.
  • Traxis Partners sold 80,000 Myriad Genetics shares in Q3 2013, an estimated $2.15M.
  • Traxis Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 1 quarter.
  • Traxis Partners's Myriad Genetics position peaked at $2.15M in Q2 2013.
  • 267 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2013.

Based on Traxis Partners's 13F filing for Q3 2013.